clazosentan
Small moleculeexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Jan 1, 2005 (NCT00111085)
Timeline
Indications
Mechanism of action
- Endothelin receptor ET-AANTAGONIST
EDNRA antagonist
Phase 3 study terminated due to lack of efficacy
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(-c2ccnc(-c3nnn[nH]3)c2)nc1OCCO- Mol. weight
- 577.58 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL109648 ↗
Also known as
- axv 034
- axv-034
- axv-034
- axv-034
- axv-034343
- axv343434
- axv 343434
- axv-343434
- axv-343434
- axv-343434
- clazosentan
- clazosentan
- clazosentan
- clazosentan
- n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1h-tetrazol-5-yl)pyridin-4-yl)pyrimidin-4-yl)-5-methylpyridine-2-sulfonamide
- ro 61-1790
- ro-61-1790
- ro-61-1790
- ro-61-1790
- vml588
- vml 588
- vml-588
- vml-588
- vml-588
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04452006 | Phase 1 | Jul 20, 2020 | Idorsia Pharmaceuticals Ltd. |
| NCT03585270 | Phase 3 | Nov 1, 2018 | Idorsia Pharmaceuticals Ltd. |
| NCT03657446 | Phase 1 | Sep 20, 2018 | Idorsia Pharmaceuticals Ltd. |
| NCT03596294 | Phase 1 | Jul 19, 2018 | Idorsia Pharmaceuticals Ltd. |
| NCT02560532 | Phase 2 | Mar 1, 2016 | Actelion |
| NCT00940095 | Phase 3 | Jul 1, 2009 | Actelion |
| NCT00558311 | Phase 3 | Nov 1, 2007 | Actelion |
| NCT00111085 | Phase 2 | Jan 1, 2005 | Actelion |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Actelion | For profit | 4 | 4 | 2 | 2005 |
| Idorsia Pharmaceuticals Ltd. | For profit | 4 | 4 | 2 | 2018 |
2 organizations
Page 1 / 1